drugset
drugset / Trial / NCT04235257

Intradermal, Fractional Dose of HPV Vaccines:

NCT04235257 ↗

Phase 4 Active not recruiting 40 enrolled University of Washington
RandomizedParallel-groupOpen-labelOther

Summary

This randomized phase IV trial compares fractional dose of bivalent HPV vaccine to fractional dose of nonavalent HPV vaccine among men and women aged 27-45 years in Seattle, Washington. Participants will have immune response assessed at baseline, 4 weeks, 6 months, 12 months, and 24 months.

Timeline

Start
2020-11-01
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Cervarix Vaccine 0.1 ml Subcutaneous
Subject Gardasil 9 Vaccine 0.1 ml Subcutaneous

Indications

human papilloma virus infection